All In Biotech

Drug Trial Radar · NCT01658826

Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes

A Double-blind, Double Dummy, Randomized Crossover Trial to Compare the Effect of "AIC316 (Pritelivir)" 100 mg Once Daily Versus Valacyclovir 500 mg Once Daily on Genital HSV Shedding in HSV-2 Seropositive Adults.

Last checked: Nov 19, 2026Latest source record: Apr 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

91

Actual

Start

Oct 2012

Primary completion

May 2013

Study completion Jul 2013

Sponsor

Sponsor type
Industry
Collaborators
Medpace, Inc.
First posted
Aug 7, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the study is to evaluate the safety and efficacy of "AIC316 (pritelivir)" 100 mg once daily compared to valacyclovir 500 mg once daily for the prevention of HSV-2 genital shedding.

Conditions

  • Genital Herpes

Interventions

  • AIC316Drug

    100 mg oral administration

  • ValacyclovirDrug

    500 mg oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Within-subject Genital HSV Mucocutaneous Shedding RateTime frame: 28 days
  2. Overall Shedding RateTime frame: 28 days

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Indiana University School of Medicine, IU Infectious Diseases Research

    Indianapolis, Indiana

  • Westover Heights Clinic

    Portland, Oregon

  • University of Texas Health Science Centre, Center for Clincial Studies

    Houston, Texas

  • University of Washington, Virology Research Clinic

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.